torcetrapib has been researched along with Elevated Cholesterol in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quintão, EC | 1 |
| Jukema, JW; Rensen, PC | 1 |
| Masterjohn, C | 1 |
| Stroes, ES; Vergeer, M | 1 |
| Arca, M; Asselbergs, FW; Boekholdt, SM; Cambien, F; Casas, JP; Cooper, J; D'Agostino, RB; Deanfield, J; Dullaart, RP; Ebrahim, S; Ford, I; Freeman, D; Gaudio, C; Goto, A; Gudnason, V; Hingorani, AD; Horne, BD; Humphries, SE; Isaacs, A; Kakko, S; Kastelein, JJ; Kauma, H; Kesäniemi, YA; Khaw, KT; Kivimaki, M; Kumari, M; Lawlor, DA; Li, TY; Marmot, M; McCaskie, P; McCormack, V; Navis, G; Nicaud, V; Okumura, K; Ordovas, J; Packard, C; Palmer, LJ; Paulweber, B; Pencina, M; Poirer, O; Quagliarini, F; Ricketts, SL; Sandhofer, A; Sandhu, MS; Sattar, N; Savolainen, MJ; Shah, T; Smeeth, L; Smith, GD; Sofat, R; Sorli, JV; Talmud, PJ; Thompson, JF; van der Harst, P; van Duijn, CM; Van Gilst, WH; van Veldhuisen, DJ; Vasan, RS; Wareham, N; Witteman, JC; Yokoyama, S | 1 |
| Funder, JW | 1 |
| von Eckardstein, A | 1 |
| Burnett, JR | 1 |
| Bamberger, MJ; Jiang, XC; Matsuura, F; Nguyen, T; Rinninger, F; Shear, CL; Tall, AR; Wang, N; Yvan-Charvet, L | 1 |
| Merrick, GS; Moyad, MA | 1 |
| Cornuz, J; Rodondi, N | 1 |
5 review(s) available for torcetrapib and Elevated Cholesterol
| Article | Year |
|---|---|
The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
Topics: Amides; Animals; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Hypercholesterolemia; Mice; Oxazolidinones; Quinolines; Rabbits; Sulfhydryl Compounds | 2016 |
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Topics: Aldosterone; Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Corticosterone; Esters; Humans; Hydrocortisone; Hypercholesterolemia; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2009 |
Aldosterone, sodium, and hypertension: lessons from torcetrapib?
Topics: Aldosterone; Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Humans; Hypercholesterolemia; Hypertension; Quinolines; Sensitivity and Specificity; Sodium | 2010 |
Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Quinolines; Risk Assessment; Treatment Failure | 2010 |
[Reading medical articles--what pitfalls to avoid].
Topics: Anticholesteremic Agents; Cholesterol, HDL; Clinical Trials as Topic; Dementia; Early Diagnosis; Education, Medical, Continuing; Humans; Hypercholesterolemia; Lung Neoplasms; Odds Ratio; Periodicals as Topic; Physicians, Family; Quinolines; Randomized Controlled Trials as Topic; Reading; Risk Factors | 2007 |
7 other study(ies) available for torcetrapib and Elevated Cholesterol
| Article | Year |
|---|---|
[Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Humans; Hypercholesterolemia; Patient Selection; Quinolines; Randomized Controlled Trials as Topic; Risk Factors; Water-Electrolyte Balance | 2008 |
Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
Topics: Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Endothelium, Vascular; Humans; Hypercholesterolemia; Oxazolidinones; Quinolines; Treatment Outcome; Triglycerides; Vitamin E | 2009 |
Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
Topics: Anticholesteremic Agents; Biomarkers; Blood Pressure; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Electrolytes; Genotype; Humans; Hypercholesterolemia; Hypertension; Lipoproteins, HDL; Polymorphism, Single Nucleotide; Quinolines; Randomized Controlled Trials as Topic; Risk Factors; White People | 2010 |
Torcetrapib + atorvastatin (Pfizer).
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines | 2005 |
Cholesterol: the good, the bad, and the stopped trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials, Phase III as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Failure | 2006 |
Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Biological Transport; Blotting, Western; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Macrophages; Mice; Mice, Knockout; Quinolines; Sterol O-Acyltransferase; Treatment Outcome | 2007 |
Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part VI--The recent rise and fall of the HDL-boosting drug torceptrapib.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Drug Industry; Exercise Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Patient Education as Topic; Quinolines; Risk Reduction Behavior; Smoking Cessation; Stress, Psychological; United States; Urologic Diseases; Weight Loss | 2007 |